Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02710032
Other study ID # R34MH104072
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 1, 2017
Est. completion date July 31, 2018

Study information

Verified date August 2018
Source University of California, Los Angeles
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators propose a social network-based PrEP adherence intervention as part of a comprehensive, context-specific approach to HIV prevention for TW in Lima, Peru. In order to be effective, PrEP-based prevention strategies need to address not only biological efficacy, but also individual behavioral decision-making processes, interpersonal partnership contexts of risk, peer norms of sexual behavior and PrEP adherence, and structural access to prevention technologies. Using a health promotion behavioral model that combines Social Action Theory with social network theories of information dissemination and collective behavior change, the investigators propose to develop and refine a network-based intervention that promotes PrEP adherence in the existing social networks of TW. Formative research will outline individual, partner-level, and network-based contexts of sexual risk behavior, patterns of social network interactions, anticipated adoption and use of new prevention technologies, and optimal content for a PrEP adherence intervention. Findings will be used to define the elements of a prevention intervention using social networks of TW and social media technologies to generate, implement, and reinforce social norms of PrEP adherence and risk behavior reduction for TW.


Description:

Pre-Exposure Prophylaxis (PrEP) has biological efficacy in reducing risk for HIV acquisition but its clinical effectiveness is strongly influenced by patient adherence, which is in turn influenced by social and behavioral factors. Trials conducted among serodiscordant heterosexual African couples who were engaged in supportive romantic partnerships found PrEP to be highly effective for HIV prevention. In contrast, studies with socially marginalized populations in Latin America without strong interpersonal support networks, such as transgender women (TW), found substantially lower levels of adherence and, as a result, effectiveness. We believe that new, social network-based strategies to promote PrEP adherence, coupled with behavioral interventions to minimize risk compensation, will be critical to controlling the spread of HIV among TW in Latin America.

TW in Peru are at high risk for HIV infection (30-33% HIV prevalence) and in urgent need of new approaches to prevention that adequately address HIV risk as part of their life contexts. Due to their social and economic marginalization and lack of support from traditional neighborhood and family networks, TW frequently neglect traditional approaches to HIV/STI prevention that have been developed for men who have sex with men (MSM), and report high rates of compensated sex, unprotected intercourse, and sexually transmitted infection (STI) co-infections. Despite their socially marginalized status, communities of TW in Lima are frequently connected through dense social and geographic networks that provide support outside of traditional community systems, disseminate new information and ideas, and define and maintain standards of behavior. While these social networks provide a critical framework for the dissemination and maintenance of TW community norms, they have not previously been used as a framework for HIV prevention.

We propose a social network-based PrEP adherence intervention as part of a comprehensive, context-specific approach to HIV prevention for TW in Lima, Peru. In order to be effective, PrEP-based prevention strategies need to address not only biological efficacy, but also individual behavioral decision-making processes, interpersonal partnership contexts of risk, peer norms of sexual behavior and PrEP adherence, and structural access to prevention technologies. Using a health promotion behavioral model that combines Social Action Theory with social network theories of information dissemination and collective behavior change, we propose to develop and refine a network-based intervention that promotes PrEP adherence in the existing social networks of TW. Formative research will outline individual, partner-level, and network-based contexts of sexual risk behavior, patterns of social network interactions, anticipated adoption and use of new prevention technologies, and optimal content for a PrEP adherence intervention. Findings will be used to define the elements of a prevention intervention using social networks of TW and social media technologies to generate, implement, and reinforce social norms of PrEP adherence and risk behavior reduction for TW.

Aim 1. To conduct an open evaluation of a social network-based PrEP adherence intervention for TW in Peru. The intervention will be piloted with a group of 10-15 TW recruited from a social network within a single geographic area. Using a dynamic process of implementation, refinement, and re-implementation over a 6-month period, we will assess acceptability and feasibility of specific intervention and evaluation components. Data will be used to finalize the study design, intervention manual, and quantitative assessment tools for the pilot randomized controlled trial.

Aim 2. To conduct a pilot RCT of a social network-based PrEP adherence intervention for TW in Peru. The investigators plan to enroll 6 social network clusters of TW (3 clusters per arm, recruited from 2 seeds matched from 3 geographical areas in Lima, Peru) (total N=90 TW enrolled [15 TW per cluster] to achieve at least N=60 TW completers [10 TW per cluster]) that will be randomized to participate in either the network-based PrEP adherence intervention or a control intervention. The primary outcome will be adherence to PrEP (measured via laboratory analysis of presence of detectable drug in serum, laboratory analysis of presence of detectable drug in hair, and participant self-report). The major secondary outcome will be behavioral risk compensation, specifically the degree to which participants in the two arms do or do not modify HIV risk behaviors while taking PrEP. Behavioral and biological assessments will be conducted at Baseline, 3-month, and 6-month intervals.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date July 31, 2018
Est. primary completion date July 31, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. 18 years of age or older;

2. Identify as male-to-female transgender (e.g., "trans," "transgender," "travesti");

3. Report behavioral risk for HIV infection (UAI with at least one HIV-infected or unknown serostatus partner in the preceding 6 months);

4. HIV-uninfected by rapid test.

Exclusion Criteria:

1. Unable to provide informed consent, including people with severe mental illness requiring immediate treatment or with mental illness limiting their ability to participate (e.g., dementia);

2. HIV infection (Rapid HIV assay positive);

3. Active Hepatitis B infection (Hepatitis B Surface Antigen positive);

4. Renal insufficiency (Creatinine Clearance <50).

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Social Network-Based Adherence Intervention
Participants in clusters randomized to the intervention arm will be asked to attend a series of weekly group workshops emphasizing a collective approach to HIV prevention and mutual support for PrEP adherence.
Social Media Platform
ii) Social Media Platform: The social media component of the intervention will include structured internet platforms designed to educate, motivate, and promote discussions of PrEP adherence within the participant network, unstructured participant-generated interactions to articulate and reinforce newly developed social norms within the network, and practical tools to support daily PrEP adherence.

Locations

Country Name City State
Peru Asociacion Civil Impacta Salud y Educacion Lima

Sponsors (4)

Lead Sponsor Collaborator
University of California, Los Angeles Asociación Civil Impacta Salud y Educación, Peru, Brown University, The Fenway Institute

Country where clinical trial is conducted

Peru, 

Outcome

Type Measure Description Time frame Safety issue
Primary Serum Drug Level Serum monitoring of Truvada drug level 6 Months
Secondary Self-reported Adherence Self-reported adherence to Truvada 6 Months
Secondary Hair Sample Drug Level Hair sample monitoring of Truvada drug level 6 Months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02135419 - Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions Phase 3
Active, not recruiting NCT02663856 - My Smart Age With HIV: Smartphone Self-assessment of Frailty
Terminated NCT02743598 - Liraglutide for HIV-associated Neurocognitive Disorder Phase 4
Completed NCT02846402 - Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda N/A
Completed NCT02921516 - Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings N/A
Completed NCT02659306 - Metformin Immunotherapy in HIV Infection Phase 1
Completed NCT02663869 - Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
Completed NCT02564341 - Targeting Effective Analgesia in Clinics for HIV - Intervention N/A
Active, not recruiting NCT02302950 - A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas N/A
Terminated NCT02109224 - Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Phase 1
Completed NCT01830595 - Lactoferrin Treatment in HIV Patients Phase 2
Completed NCT01852942 - Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV Phase 2
Completed NCT02269605 - Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment Phase 1
Terminated NCT01902186 - Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir Phase 4
Completed NCT02527135 - Text Messaging to Improve HIV Testing Among Young Women in Kenya N/A
Completed NCT02118168 - Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002 N/A
Completed NCT02525146 - Birmingham Access to Care Study N/A
Completed NCT01946217 - Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials N/A
Active, not recruiting NCT02602418 - Neural Correlates of Working Memory Training for HIV Patients N/A
Completed NCT01702974 - Immune Reconstitution in HIV Disease (IREHIV) Phase 2